💊Production of Liposome Drugs Utilizing Proprietary Technologies Including Anti-Cancer Agent FF-10832 New Manufacturing Facility to be Built at Toyama Chemical, a Fujifilm Company

By Drugs, Pharmaceutical

💊Production of Liposome Drugs Utilizing Proprietary Technologies Including Anti-Cancer Agent FF-10832 New Manufacturing Facility to be Built at Toyama Chemical, a Fujifilm Company.

Production of Liposome Drugs Utilizing Proprietary Technologies Including Anti-Cancer Agent FF-10832

New Manufacturing Facility to be Built at Toyama Chemical, a Fujifilm Company

Advanced production system utilizing cutting edge ICT technologies to be adopted,

company to invest approximately 4 billion yen

February 22, 2018

Press Center | Fujifilm USA

http://www.fujifilmusa.com/press/news/display_news?newsID=881367

More from tokioX :

  1. Fujifilm to invest 928 million USD to expand its large scale biologics production facility in Denmark
  2. Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19.
  3. Japan: anti-influenza drug, ‘Avigan Tablet’ recommended: Fujifilm Development
  4. Fujifilm to Set Up iPS Cell Production Facility in U.S.
  5. 💊Fujifilm accelerates new drug development for diagnostic and therapeutic drugs through the merger of group companies to form FUJIFILM Toyama Chemical Co., Ltd.
  6. 🍀Fujifilm to acquire Irvine Scientific Sales Company and IS Japan, leading companies of cell culture media.
  7. 💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)  20170927